Biogen (NASDAQ:BIIB) has received mixed analyst ratings over the past three months, with a total of 20 analysts offering their evaluations. The sentiment has shifted slightly towards a more cautious stance, with the latest 12-month price target averaging $294.95, marking a 4.71% decrease from the previous target of $309.54. Analysts from firms including JP Morgan, Barclays, and Truist Securities have adjusted their ratings and price targets, reflecting a nuanced view of Biogen's market position and financial performance. Despite facing revenue challenges and a decline in top-line earnings by -6.2%, Biogen continues to be a key player in the biotechnology sector, marketing a range of drugs for multiple sclerosis, Alzheimer's, and other conditions.